Bleeding Disorders
- Business
Data at EAHAD 2021 Highlight Value of Takeda’s Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements
Osaka, Japan: − Seven Year Data Reinforce Long-term Efficacy and Safety Review of ADVATE (Antihemophilic Factor [Recombinant]) − Abstracts Support…
Read More » - Health
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
Osaka, Japan & Cambridge, Mass., United States: – Key learnings from real-world data and retrospective studies from nine abstracts are presented…
Read More »